COAG
Hemab Therapeutics Holdings, Inc. · Healthcare
Insiders bought $55.5M net in the last 90 days ·0 sellers, 1 buyer· latest Form 4 filed Jun 17, 2026
Insider Buying
$55.5M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Latest filing
Jun 17, 2026
RA CAPITAL MANAGEMENT, L.P.
Hemab Therapeutics Holdings, Inc. (COAG) has 7 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jun 17, 2026.
Inside the rolling window, 1 insider at Hemab Therapeutics Holdings, Inc. reported 11 open-market purchases totaling $55.5M and no open-market sales. The most active filer is 10% Owner RA CAPITAL MANAGEMENT, L.P. with 11 filings. Insiders have net bought $55.5M over the trailing 6 months. The largest single insider purchase in this window was $48.1M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on May 4, 2026. The most recent open-market filing is a purchase of 6,146 shares by 10% Owner RA CAPITAL MANAGEMENT, L.P., dated Jun 15, 2026, worth $153K.
- Industry:Biotechnology
- CEO:Benny Sorensen
- Employees:59
- HQ:Cambridge, MA, US
- IPO:2026-05-01
| Source | |||||||
|---|---|---|---|---|---|---|---|
| 10% Owner | Purchase | 6,146 | $153K | Jun 17 | +53.0% | SEC ↗ | |
| 10% Owner | Purchase | 61,523 | $1.5M | Jun 17 | +53.0% | SEC ↗ | |
| 10% Owner | Purchase | 3,802 | $95K | May 21 | +53.9% | SEC ↗ | |
| 10% Owner | Purchase | 996 | $25K | May 21 | +53.9% | SEC ↗ | |
| 10% Owner | Purchase | 6,387 | $159K | May 14 | +42.7% | SEC ↗ | |
| 10% Owner | Purchase | 9,906 | $242K | May 11 | +61.9% | SEC ↗ | |
| 10% Owner | Purchase | 1,483 | $37K | May 11 | +61.9% | SEC ↗ | |
| 10% Owner | Purchase | 39,869 | $989K | May 11 | +61.9% | SEC ↗ | |
| Director, 10% Owner | Purchase | 2,675,000 | $48.1M | May 6 | — | SEC ↗ | |
| Director, 10% Owner | Purchase | 97,411 | $2.4M | May 6 | — | SEC ↗ | |
| Director, 10% Owner | Purchase | 68,018 | $1.7M | May 6 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does COAG have?
Hemab Therapeutics Holdings, Inc. (COAG) has 7 SEC Form 4 filings (22 transaction rows) in the rolling 365-day window, disclosed by 1 distinct insider. Most recent filing: Jun 17, 2026.
When was the most recent SEC Form 4 filing for COAG?
The most recent Form 4 filing for COAG on Tracefour is dated Jun 17, 2026.
Who is the most active insider at COAG?
The most active SEC Form 4 filer at COAG in the rolling window is 10% Owner RA CAPITAL MANAGEMENT, L.P., with 11 filings.
What is the net insider flow at COAG over the last 6 months?
Over the trailing 180 days, insiders at COAG have net bought $55.5M based on SEC Form 4 disclosures.
What was the largest insider purchase at COAG?
The largest single insider open-market purchase at COAG in the rolling window was $48.1M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on 2026-05-04.
What is the total insider buy and sell value at COAG in the current window?
Inside the rolling window, insiders at COAG bought $55.5M and sold $0 based on SEC Form 4 filings.
Can I get alerts for COAG insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Hemab Therapeutics Holdings, Inc. (COAG). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Hemab Therapeutics Holdings, Inc. is in the Healthcare sector.